| Rapid changes in microRNA-146a expression negatively regulate the IL-1β-induced inflammatory response in human lung alveolar epithelial cells MM Perry, SA Moschos, AE Williams, NJ Shepherd, HM Larner-Svensson, ... The Journal of Immunology 180 (8), 5689-5698, 2008 | 593 | 2008 |
| Lung delivery studies using siRNA conjugated to TAT (48− 60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity SA Moschos, SW Jones, MM Perry, AE Williams, JS Erjefalt, JJ Turner, ... Bioconjugate chemistry 18 (5), 1450-1459, 2007 | 430 | 2007 |
| Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti … SA Moschos, AE Williams, MM Perry, MA Birrell, MG Belvisi, MA Lindsay BMC genomics 8, 1-12, 2007 | 368 | 2007 |
| A new threat from an old enemy: Re‑emergence of coronavirus AO Docea, A Tsatsakis, D Albulescu, O Cristea, O Zlatian, M Vinceti, ... International journal of molecular medicine 45 (6), 1631-1643, 2020 | 291 | 2020 |
| Role of miRNA-146a in the regulation of the innate immune response and cancer AE Williams, MM Perry, SA Moschos, HM Larner-Svensson, MA Lindsay Biochemical Society Transactions 36 (6), 1211-1215, 2008 | 255 | 2008 |
| Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma E Tsitsiou, AE Williams, SA Moschos, K Patel, C Rossios, X Jiang, ... Journal of Allergy and Clinical Immunology 129 (1), 95-103, 2012 | 235 | 2012 |
| Maternally imprinted microRNAs are differentially expressed during mouse and human lung development AE Williams, SA Moschos, MM Perry, PJ Barnes, MA Lindsay Developmental dynamics: an official publication of the American Association …, 2007 | 201 | 2007 |
| MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity JJ Turner, SW Jones, SA Moschos, MA Lindsay, MJ Gait Molecular bioSystems 3 (1), 43-50, 2006 | 199 | 2006 |
| A multinational Delphi consensus to end the COVID-19 public health threat JV Lazarus, D Romero, CJ Kopka, SA Karim, LJ Abu-Raddad, G Almeida, ... Nature 611 (7935), 332-345, 2022 | 193 | 2022 |
| Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies GM Nitulescu, H Paunescu, SA Moschos, D Petrakis, G Nitulescu, ... International journal of molecular medicine 46 (2), 467-488, 2020 | 142 | 2020 |
| Extracellular vesicles and their nucleic acids for biomarker discovery F Momen-Heravi, SJ Getting, SA Moschos Pharmacology & therapeutics 192, 170-187, 2018 | 111 | 2018 |
| Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense SA Moschos, M Frick, B Taylor, P Turnpenny, H Graves, KG Spink, ... Molecular Therapy 19 (12), 2163-2168, 2011 | 106 | 2011 |
| microRNA expression in the aging mouse lung AE Williams, MM Perry, SA Moschos, MA Lindsay BMC genomics 8, 1-6, 2007 | 99 | 2007 |
| Cell-penetrating-peptide-mediated siRNA lung delivery SA Moschos, AE Williams, MA Lindsay Biochemical Society Transactions 35 (4), 807-810, 2007 | 81 | 2007 |
| Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model DA Suhy, SC Kao, T Mao, L Whiteley, H Denise, B Souberbielle, ... Molecular Therapy 20 (9), 1737-1749, 2012 | 71 | 2012 |
| Adjuvant synergy: the effects of nasal coadministration of adjuvants SA Moschos, VW Bramwell, S Somavarapu, HO Alpar Immunology and cell biology 82 (6), 628-637, 2004 | 67 | 2004 |
| Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome … C Laxton, K Brady, S Moschos, P Turnpenny, J Rawal, DC Pryde, ... Antimicrobial agents and chemotherapy 55 (7), 3105-3114, 2011 | 63 | 2011 |
| Relevance of systems pharmacology in drug discovery L Cucurull-Sanchez, KG Spink, SA Moschos Drug discovery today 17 (13-14), 665-670, 2012 | 44 | 2012 |
| Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation SA Moschos, VW Bramwell, S Somavarapu, HO Alpar Vaccine 23 (16), 1923-1930, 2005 | 40 | 2005 |
| The emerging field of venom-microbiomics for exploring venom as a microenvironment, and the corresponding Initiative for Venom Associated Microbes and Parasites (iVAMP) S Ul-Hasan, E Rodríguez-Román, AM Reitzel, RMM Adams, V Herzig, ... Toxicon: X 4, 100016, 2019 | 30 | 2019 |
Mark LindsayUniversity of Bath在 bath.ac.uk 的电子邮件经过验证
